Literature DB >> 16112187

Role of matrix metalloproteinases in inflammatory bowel disease.

Yuji Naito1, Toshikazu Yoshikawa.   

Abstract

Recent evidence demonstrates that the increased expression and activity of matrix metalloproteinases (MMPs) may contribute to intestinal tissue injury and inflammation in inflammatory bowel disease, and that MMP inhibition might be a new therapeutic approach to controlling inflammatory response. In addition, MMPs may play a crucial role in physiological and pathophysiological reactions such as leukocyte accumulation into inflamed tissue, cytokine production from inflammatory and epithelial cells, T lymphocyte homing to the intestine, wound healing and proliferation of epithelial cells, and intestinal innate immunity. This review focuses on recent progress in elucidating the biological and pathological roles of MMPs in inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16112187     DOI: 10.1016/j.mam.2005.07.009

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  38 in total

Review 1.  Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases.

Authors:  Madharasi V A Pichai; Lynnette R Ferguson
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

2.  Effects of curcumin and Ginkgo biloba on matrix metalloproteinases gene expression and other biomarkers of inflammatory bowel disease.

Authors:  Tarek Kamal Motawi; Sherine Maher Rizk; Ahmed Hassan Shehata
Journal:  J Physiol Biochem       Date:  2012-04-26       Impact factor: 4.158

Review 3.  Do we really understand what the immunological disturbances in inflammatory bowel disease mean?

Authors:  Epameinondas V Tsianos; Konstantinos Katsanos
Journal:  World J Gastroenterol       Date:  2009-02-07       Impact factor: 5.742

4.  Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity.

Authors:  Heng Li; Chen Fan; Chunlan Feng; Yanwei Wu; Huimin Lu; Peilan He; Xiaoqian Yang; Fenghua Zhu; Qing Qi; Yuanzhuo Gao; Jianping Zuo; Wei Tang
Journal:  Br J Pharmacol       Date:  2019-05-17       Impact factor: 8.739

5.  Notch1 regulates the effects of matrix metalloproteinase-9 on colitis-associated cancer in mice.

Authors:  Pallavi Garg; Sabrina Jeppsson; Guillaume Dalmasso; Amr M Ghaleb; Beth B McConnell; Vincent W Yang; Andrew T Gewirtz; Didier Merlin; Shanthi V Sitaraman
Journal:  Gastroenterology       Date:  2011-06-30       Impact factor: 22.682

6.  Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis.

Authors:  Prashant Nighot; Rana Al-Sadi; Manmeet Rawat; Shuhong Guo; D Martin Watterson; Thomas Ma
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-10-29       Impact factor: 4.052

7.  Expression of matrix metalloproteinase-1 and tumor necrosis factor-alpha in ulcerative colitis.

Authors:  Ying-De Wang; Jing-Wei Mao
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

8.  Protective role of metalloproteinase inhibitor (AE-941) on ulcerative colitis in rats.

Authors:  Jing-Wei Mao; Xiao-Mei He; Hai-Ying Tang; Ying-De Wang
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

9.  A local imbalance between MMP and TIMP may have an implication on the severity and course of appendicitis.

Authors:  Anna Solberg; Lena Holmdahl; Peter Falk; Ingrid Palmgren; Marie-Louise Ivarsson
Journal:  Int J Colorectal Dis       Date:  2008-03-18       Impact factor: 2.571

10.  Lipid alterations in experimental murine colitis: role of ceramide and imipramine for matrix metalloproteinase-1 expression.

Authors:  Jessica Bauer; Gerhard Liebisch; Claudia Hofmann; Christian Huy; Gerd Schmitz; Florian Obermeier; Jürgen Bock
Journal:  PLoS One       Date:  2009-09-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.